10 results on '"Santos-López, Gerardo"'
Search Results
2. Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages.
- Author
-
Reyes-Vallejo, Tania, Conde-Rodríguez, Ileana, Serna-Villalobos, Jocelyn, Ramírez-Díaz, Ivonne, Pérez-Villalobos, Gabriela, Delgado-López, Guadalupe, Vazquez-Zamora, Víctor Javier, Gutiérrez-Quiroz, Claudia Teresita, Ávila-Jiménez, Laura, García-Carrancá, Alejandro, Martínez-Acosta, Liliana, Santos-López, Gerardo, Reyes-Leyva, Julio, and Vallejo-Ruiz, Verónica
- Subjects
CERVICAL cancer ,CANCER patients ,CERVICAL intraepithelial neoplasia ,PRECANCEROUS conditions ,RECEIVER operating characteristic curves ,CANCER invasiveness - Abstract
Purpose: Cervical cancer (CC) is the second most frequent cancer in undeveloped countries. Serum biomarkers could be useful for evaluation of the treatment response and as a complementary means to improve diagnosis. The expression of galectin-9 is altered in cancer tissue, and higher concentrations are found in the serum of cancer patients. The objectives of this study were (a) to determine the serum galectin-9 concentration in patients with intraepithelial lesions and CC, (b) to determine if the concentration was related to the clinicopathological characteristics and (c) to determine if the galectin-9 concentration was related to its expression level in tumour tissue. Patients and Methods: In all, 222 serum samples from women with different diagnoses, including premalignant lesions and CC, as well as samples from women with normal cytology were included in the study. The serum galectin-9 concentration was determined by ELISA. To evaluate the expression level of galectin-9 in CC tissue, immunohistochemistry was performed in 34 CC biopsy specimens. Results: The galectin-9 concentration in the serum of CC patients (8.171 ng/mL) was increased compared with serum from women with normal epithelia (4.654 ng/mL) and those with low-grade (4.806 ng/mL) and high-grade (5.354 ng/mL) intraepithelial lesions (p value < 0.0001). The area under the ROC curve considering the CC group and the control group was 0.882. The optimal cut-off value was ≥ 6.88 ng/mL, the specificity obtained was 100%, and the sensitivity was 68.2%. In the CC group, the analysis of the clinical stage showed an increase of galectin-9 in the advanced stage IV group. Serum galectin-9 was not related to the level of galectin-9 expression in tissue, which suggests that galectin-9 is not secreted by tumour cells. Conclusion: The serum galectin-9 concentration is related to cancer progression, as the level of this protein is higher in patients with advanced-stage disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Sialyl Lewis x expression in cervical scrapes of premalignant lesions
- Author
-
Velázquez-Márquez, Noé, Santos-López, Gerardo, Jiménez-Aranda, Lucio, Reyes-Leyva, Julio, and Vallejo-Ruiz, Verónica
- Published
- 2012
- Full Text
- View/download PDF
4. Glycogene expression profiles from a HaCaT cell line stably transfected with HPV16 E5 oncogene.
- Author
-
CISNEROS-RAMÍREZ, DENISSE, MARTÍNEZ-LAGUNA, YGNACIO, MARTÍNEZ-MORALES, PATRICIA, ADRIANAAGUILAR-LEMARROY, JAVE-SUÁREZ, LUIS FELIPE, SANTOS-LÓPEZ, GERARDO, REYES-LEYVA, JULIO, and VALLEJO-RUIZ, VERÓNICA
- Subjects
CELL lines ,PAPILLOMAVIRUS diseases ,MESSENGER RNA ,CELL transformation ,PROTEIN expression ,CERVICAL cancer - Abstract
The altered expression of glycan antigens has been reported during cervix transformation, demonstrating increased mRNA levels of certain glycogenes. Human papillomavirus (HPV) is the aetiological agent of cervical cancer. High risk HPV E5 is considered an oncogene and has been implicated in cell transformation. E6 and E7 HPV oncoproteins modify the expression of certain glycogenes. The role of the E5 HPV protein in glycogene expression changes has not yet been reported. The aim of the present study was to determine the effects of HPV16 E5 oncoprotein on glycogene expression. For these, a microarray assay was performed using the HaCaT cell line and altered glycogenes were identified. The mRNA levels of certain glycogenes were determined via reverse transcription‑quantitative PCR (RT‑qPCR). Using in silico analysis, the present study identified that glycosylation pathways were altered by E5. Microarray analysis revealed alterations in certain glycogenes, including the upregulation of ST6GAL1, ST3GAL3, CHST2 and MANBA, and the downregulation of UGT2B15, GALNT11, NDST2 and UGT1A10. Increased mRNA levels were confirmed via RT‑qPCR for sialyltransferases genes. Additionally, in silico analysis was performed to identify glycosylation networks altered in the presence of the E5 oncoprotein. The analysis revealed that E5 could modify glycan sialylation, the N‑glycosylation pathway, keratan sulfate and glycosaminoglycan synthesis. To the best of our knowledge, the current study was the first to determine the role of the HPV16 E5 oncoprotein in glycogene expression changes. The results indicated that increased sialyltransferase mRNA levels reported in pre‑malignant and malignant cervical tissues could be the result of E5 oncoprotein expression. The results provide a possible role of HPV infection on glycosylation changes reported during cervix transformation. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Response to Article "Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages" [Response to Letter].
- Author
-
Reyes-Vallejo, Tania, Conde-Rodríguez, Ileana, Serna-Villalobos, Jocelyn, Ramírez-Díaz, Ivonne, Pérez-Villalobos, Gabriela, Delgado-López, Guadalupe, Vazquez-Zamora, Víctor Javier, Gutiérrez-Quiroz, Claudia Teresita, Ávila-Jiménez, Laura, García-Carrancá, Alejandro, Martínez-Acosta, Liliana, Santos-López, Gerardo, Reyes-Leyva, Julio, and Vallejo-Ruiz, Verónica
- Subjects
CERVICAL cancer ,CANCER patients - Abstract
Tania Reyes-Vallejo, SP 1 sp Ileana Conde-Rodríguez, SP 2 sp Jocelyn Serna-Villalobos, SP 2 sp Ivonne Ramírez-Díaz, SP 2 sp Gabriela Pérez-Villalobos, SP 3 sp Guadalupe Delgado-López, SP 4 sp Víctor Javier Vázquez-Zamora, SP 5 sp Claudia Teresita Gutierrez-Quiroz, SP 5 sp Laura Ávila-Jiménez, SP 6 sp Alejandro García-Carrancá, SP 7 sp Liliana Martínez-Acosta, SP 8 sp Gerardo Santos-López, SP 4 sp Julio Reyes-Leyva, SP 9 sp Verónica Vallejo-Ruiz SP 4 sp SP 1 sp Departamento de Ciencias Químico-Biológicas, Universidad de las Américas Puebla, Puebla, México; SP 2 sp Posgrado en Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, México; SP 3 sp Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, México; SP 4 sp Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Atlixco, Puebla, México; SP 5 sp Hospital de Especialidades, General Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, México; SP 6 sp Organo de Operación Administrativa Desconcentrada Estatal Morelos, Instituto Mexicano del Seguro Social, Cuernavaca, Morelos, México; SP 7 sp Universidad Nacional Autónoma de México Instituto Nacional de Cancerología, Ciudad de México, México; SP 8 sp Hospital General de Zona No. 5, Instituto Mexicano del Seguro Social, Metepec, Puebla, México; SP 9 sp Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, México Correspondence: Verónica Vallejo-Ruiz, Km 4.5 Carretera Federal Atlixco-Metepec, Atlixco, Puebla, Z.C. 74360, Mexico, Tel +52 24 44 440 122, Email [email protected]; [email protected]gob.mx View the original paper by Ms Reyes-Vallejo and colleagues This is in response to the Letter to the Editor Dear editor We appreciate the comments of Panjaitan et al regarding our recent publication. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
6. Expression analysis of ST3GAL4 transcripts in cervical cancer cells.
- Author
-
Cruz, Lorena Roa-De La, Martínez-Morales, Patricia, Morán-Cruz, Irene, Milflores-Flores, Lorena, Rosas-Murrieta, Nora, González-Ramírez, César, Ortiz-Mateos, Claudia, Monterrosas-Santamaría, Ricardo, González-Frías, Celestina, Rodea-Ávila, Carlos, Apresa-García, Teresa, Aguilar-Lemarroy, Adriana, Jave-Suarez, Luis, Santos-López, Gerardo, Reyes-Leyva, Julio, and Vallejo-Ruiz, Verónica
- Subjects
CERVICAL cancer ,MESSENGER RNA ,REVERSE transcriptase polymerase chain reaction ,SIALYLTRANSFERASES ,ANTIGENS - Abstract
ST3GAL4 gene expression is altered in different cancer types, including cervical cancer. Several mRNA transcripts have been reported for this gene; however, their expression levels in cervical cancer have not been analyzed. ST3GAL4 encodes for β-galactosidase α-2,3-sialyltransferase 4, involved in the biosynthesis of the tumour antigens sLe(x) and sulfo-sLe(x). The present study evaluated the presence of three mRNA variants (V1, V2 and V3) in cervical cancer cell lines, detecting the three variants. Additionally, the expression level of the V1 transcript of the ST3GAL4 gene was determined by reverse transcription-quantitative polymerase chain reaction in cervical cell lines and in normal, premalignant and cervical cancer tissue. The V1 transcript of the ST3GAL4 demonstrated significant decreased expression in premalignant and malignant cervical tissues. The results suggested that deregulation of this gene could occur prior to the presence of cancer and demonstrated the importance of evaluating the expression level of V1, and its association with disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. La oncoproteína E7 del virus de papiloma humano y su papel en la transformación celular.
- Author
-
Vallejo-Ruiz, Verónica, Velázquez-Márquez, Noé, Sánchez-Alonso, Patricia, Santos-López, Gerardo, and Reyes-Leyva, Julio
- Abstract
Copyright of Revista Medica del IMSS is the property of Direccion de Prestaciones Medicas - IMSS and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2015
8. Human papillomavirus infections in Mexican women with normal cytology, precancerous lesions, and cervical cancer: Type-specific prevalence and HPV coinfections.
- Author
-
Aguilar‐Lemarroy, Adriana, Vallejo‐Ruiz, Verónica, Cortés‐Gutiérrez, Elva I, Salgado‐Bernabé, Manuel Eduardo, Ramos‐González, Norma Patricia, Ortega‐Cervantes, Laura, Arias‐Flores, Rafael, Medina‐Díaz, Irma M, Hernández‐Garza, Fernando, Santos‐López, Gerardo, and Piña‐Sánchez, Patricia
- Abstract
The prevalence and genotype distribution of human papillomavirus (HPV) provides the basis for designing HPV prevention programs. The prevalence rates of type-specific HPV and coinfections in samples of Mexican women were investigated in 822 women aged 18-87 years. HPV detection was performed using a Linear Array
TM genotyping test. HPV infection was found in 12.4% of controls, 46.3% of those with cervical intraepithelial neoplasia 1, and 100% of those with cervical intraepithelial neoplasia 3 or cervical cancer. HPV 16 was the most prevalent type in all diagnosis groups. The HPV types most frequently found in cervical cancers were 16, 18, 45, 52, 58, and 39; HPV types 16, 62, 51, 84, 18, 53, and CP6108 were the most prevalent in control women. Considering HPV-positive samples only, coinfections occurred most often in controls (63%) and were less frequent in those with cervical cancer (26%). The most frequent viral types in coinfections with HPV 16 in control women were HPV 62, 51, and 84; in women with cervical cancers, HPV 18, 39, and 70 were most common. In conclusion, in addition to HPV types 16 and 18, types 45, 39, 58, 52, and 71 were found in cervical cancers in Mexican women (78%); among them, only 65% were attributable to HPV types 16 and 18. Therefore, it is necessary to consider these viral types in the design of new vaccines, and to determine whether certain HPV types coinfecting with HPV 16 in precursor lesions determine tumor progression or regression. J. Med. Virol. 87:871-884, 2015. © 2015 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
9. Characterization of P1 promoter activity of the β-galactoside α2,6sialyltransferase I gene (s iat 1) in cervical and hepatic cancer cell lines.
- Author
-
Milflores-Flores, Lorena, Millán-Pérez, Lourdes, Santos-López, Gerardo, Reyes-Leyva, Julio, and Vallejo-Ruiz, Verónica
- Subjects
PROMOTERS (Genetics) ,CANCER cells ,GALACTOSIDES ,SIALYLTRANSFERASES ,GALACTOSIDASES ,LUCIFERASES ,CERVICAL cancer ,LIVER cancer - Abstract
The level of β-galactoside α2,6sialyltransferase I (ST6Gal I) mRNA, encoded by the gene siat1, is increased in malignant tissues. Expression is regulated by different promoters - P1, P2 and P3 - generating three mRNA isoforms H, X and YZ. In cervical cancer tissue the mRNA isoform H, which results from P1 promoter activity, is increased. To study the regulation of P1 promoter, different constructs from P1 promoter were evaluated by luciferase assays in cervical and hepatic cell lines. Deletion of a fragment of 1048 bp (−89 to +24 bp) increased 5- and 3-fold the promoter activity in C33A and HepG2 cell lines, respectively. The minimal region with promoter activity was a 37 bp fragment in C33A cells. The activity of this region does not require the presence of an initiator sequence. In HepG2 cells the minimal promoter activity was detected in the 66 bp fragment. Sp1 (−32) mutation increased the promoter activity only in HepG2 cells. HNF1 mutation decreased promoter activity in HepG2 cell line but not in C33A cells. We identified a large region that plays a negative regulation role. The regulation of promoter activity is cell type specific. Our study provides new insights into the complex transcriptional regulation of siat1 gene. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
10. Increased expression of sialic acid in cervical biopsies with squamous intraepithelial lesions.
- Author
-
López-Morales, Dolores, Reyes-Leyva, Julio, Santos-López, Gerardo, Zenteno, Edgar, and Vallejo-Ruiz, Verónica
- Subjects
SIALIC acids ,GENETIC transformation ,CARCINOGENESIS ,METASTASIS ,CERVICAL cancer ,GLYCOCONJUGATES - Abstract
Background: Altered sialylation has been observed during oncogenic transformation. Sialylated oligosaccharides of glycoproteins and glycolipids have been implicated in tumor progression and metastases. In the cervical cancer high levels of sialic acid have been reported in the patients serum, and an increased of total sialic acid concentration has been reported for the cervical neoplasia and cervical cancer. This study investigates the changes in expression and distribution of α2,3-linked sialic acid and α2,6- linked sialic acid in low and high squamous intraepithelial lesions and in normal tissue. Methods: Lectin histochemistry was used to examine the expression and distribution of sialic acid in different grades of cervical neoplasia. We applied Maackia amurensis lectin, which interacts with α2,3-linked sialic acid and Sambucus nigra lectin specific for α2,6-linked sialic acid. Results: The histochemical analysis showed that α2,3-linked sialic acid and α2,6- linked sialic acid increased in intensity and distribution in concordance with the grade of squamous intraepithelial lesion (SIL). These results are in concordance with a previous study that reports increased RNAm levels of three sialyltransferases. Conclusions: These results show that the change in sialylation occurs before cancer development and may play an important role in cellular transformation. These findings provide the basis for more detailed studies of the possible role of cell surface glycoconjugates bearing sialic acid in the cellular cervix transformation. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.